Overview

Boceprevir in End Stage Renal Disease (ESRD)

Status:
Withdrawn

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the safety and efficacy of triple therapy with pegylated interferon (P-IFN), ribavirin and boceprevir in patients with genotype 1 chronic Hepatitis C Virus (HCV) infection and end stage renal disease (ESRD) on hemodialysis (HD).

Phase:

N/A

Details

Lead Sponsor:

Columbia University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Interferon alpha-2
Interferon-alfa-1b
Interferon-alpha
Interferons
Peginterferon alfa-2a
Peginterferon alfa-2b
Ribavirin